Oxcarbazepine (Oxtellar XR)
Small molecule
Evidence outlook
Approved: Epilepsy, Focal Onset Seizures
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PROSPER1 NCT00772603 · Epilepsies, Partial The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive. Registry: NCT00772603 | 3 | PCH(T), ITT (Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline) 2010-04 | PCH(T), ITT (Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline): 2400mg/Day SPN-804 -42.9 percentage of change (range -100 to 212.8) | 1200mg/Day SPN-804 -38.2 percentage of change (range -100 to 556.1) | Placebo -28.7 percentage of change (range -100 to 333.6) | Partial signal | link ↗ |
View 1 more trial
NCT00908349 NCT00908349 · Partial Epilepsy The study was an open-label, single-arm continuation of the randomized 804P301 trial, with 214 participants and no placebo or active comparator. Its clinical primary measure showed a median 26.3% reduction in seizure rate, but the single-arm design cannot establish comparative treatment efficacy. Registry: NCT00908349 | 3 | Percent Change in Seizure Rate (one year) 2011-11 | Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Voltage-gated sodium channel drugs
Eslicarbazepine acetate, Fosphenytoin, Lamotrigine, Oxcarbazepine (Trileptal), Rufinamide and 1 more. Compare all 7 Voltage-gated sodium channel drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Oxcarbazepine (Oxtellar XR): this drug | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | Featured results are non-efficacy only in this race | |
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | Partial signal | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Partial signal | NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Carbamazepine | Approved | Small molecule | Sodium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | Weak signal | NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8) NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Diastat) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed | |
| Ethosuximide | Approved | Small molecule | T-type calcium channel | Reliable signal | NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted. | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | Reliable signal | NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses. | |
| Felbamate | Approved | Small molecule | NMDA receptor (glycine site, antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Fosphenytoin | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | No reviewed efficacy summary in this indication | |
| Gabapentin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Partial signal | NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms. NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed | |
| Lacosamide (Vimpat) | Approved | Small molecule | Voltage-gated sodium channels | Reliable signal | NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure). | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | Weak signal | NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20 | |
| Levetiracetam (Elepsia XR) | ApprovedUS marketing discontinued | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | not yet graded | No reviewed efficacy summary in this indication | |
| Levetiracetam (Keppra XR) | Approved | Small molecule | Synaptic vesicle protein 2A (SV2A) | Partial signal | Featured results are non-efficacy only in this race | |
| Levetiracetam (Keppra) | Approved | Small molecule | Synaptic vesicle protein 2A (SV2A) | Partial signal | NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6) NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002). | |
| Lorazepam | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Midazolam (Nayzilam) | Approved | Small molecule | GABA-A receptor, GABA-A receptor (benzodiazepine site) | Reliable signal | NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed | |
| Oxcarbazepine (Trileptal) | Approved | Small molecule | Voltage-gated sodium channel | Weak signal | NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. | |
| Perampanel (Fycompa) | Approved | Small molecule | AMPA receptor (antagonist) | Weak signal | NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results). NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013). | |
| Phenobarbital Sodium Injection (Sezaby) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Phenytoin | Approved | Small molecule | Voltage-gated sodium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Weak signal | NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed | |
| Primidone | Approved | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Tiagabine | Approved | Small molecule | GABA transporter (uptake carrier) | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Eprontia) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Qudexy XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Reliable signal | NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) | |
| Topiramate (Topamax Sprinkle) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Partial signal | NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group. | |
| Topiramate (Trokendi XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Valproate | ApprovedUS marketing discontinued | Small molecule | GABAergic neurotransmission | Partial signal | NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | Partial signal | NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Zonisamide (Zonegran) | Approved | Small molecule | Voltage-gated sodium channels | Weak signal | Featured results are non-efficacy only in this race | |
| Zonisamide (Zonisade) | Approved | Small molecule | Voltage-gated sodium and T-type calcium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Azetukalner | Phase 3 | Small molecule | Kv7 potassium channel | Reliable signal | NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% | |
| Bexicaserin | Phase 3 | Small molecule | Serotonin 5-HT2C receptor (agonist) | Partial signal | NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed | |
| Carisbamate | Phase 3 | Small molecule | Voltage-gated sodium channel | Partial signal | NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed | |
| Clemizole (EPX-100) | Phase 3 | Small molecule | Histamine H1 receptor, Serotonin receptors (5-HT) | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Libervant) | Phase 3 | Small molecule | GABA-A receptor | Weak signal | Featured results are safety only in this race | |
| Elsunersen | Phase 3 | RNA / oligonucleotide | SCN2A (antisense knockdown) | Partial signal | NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06). | |
| RAP-219 | Phase 3 | Small molecule | AMPA receptor (TARP γ8-dependent) | Weak signal | NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001) | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| Staccato Alprazolam | Phase 3 | Small molecule | GABA-A receptor | Reliable signal | NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) | |
| Vormatrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (NaV1.2 / NaV1.6) | Partial signal | NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed | |
| YCJ-01 | Phase 3 | Botanical | Cannabinoids (full-spectrum cannabis extract) | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (JZP926) | Phase 2/3 | Small molecule | Cannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoid | not yet graded | No reviewed efficacy summary in this indication | |
| Opakalim | Phase 2/3 | Small molecule | Kv7 potassium channel | Weak signal | NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26). | |
| ABS-1230 | Phase 2 | Small molecule | KCNT1 (KNa1.1/Slack) channel | not yet graded | No reviewed efficacy summary in this indication | |
| AV078 | Phase 2 | Small molecule | mTORC1 (mammalian target of rapamycin complex 1) (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| CB03-154 | Phase 2 | Small molecule | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener) | not yet graded | No reviewed efficacy summary in this indication | |
| Huperzine A (SPN-817) | Phase 2 | Small molecule | Acetylcholinesterase | Weak signal | NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events. | |
| NPT2042 | Phase 2 | Small molecule | NKCC1 | Partial signal | No reviewed efficacy summary in this indication | |
| AMT-260 | Phase 1/2 | Gene therapy / editing | GRIK2 (GluK2-containing kainate receptor) | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 66 furthest-along competitors are listed; 7 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.